|
|
Volumn 6, Issue 2, 2009, Pages 83-
|
|
Prime time for a polypill after myocardial infarction?
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ACETYLSALICYLIC ACID;
ACETYLSALICYLIC ACID PLUS ATENOLOL PLUS RAMIPRIL PLUS SIMVASTATIN PLUS THIAZIDE;
ACETYLSALICYLIC ACID PLUS RAMIPRIL PLUS SIMVASTATIN;
BETA ADRENERGIC RECEPTOR BLOCKING AGENT;
CARDIOVASCULAR AGENT;
DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;
HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;
UNCLASSIFIED DRUG;
CARDIOVASCULAR DISEASE;
CARDIOVASCULAR RISK;
CLINICAL TRIAL;
DRUG DESIGN;
DRUG DOSAGE FORM;
DRUG FORMULATION;
EDITORIAL;
HEALTH CARE AVAILABILITY;
HEART INFARCTION;
HIGH RISK POPULATION;
HUMAN;
MORTALITY;
PATIENT COMPLIANCE;
POLYPHARMACY;
POLYPILL;
PRIORITY JOURNAL;
SECONDARY PREVENTION;
CARDIOVASCULAR AGENTS;
COST SAVINGS;
DRUG COMBINATIONS;
DRUG COSTS;
HEALTH CARE COSTS;
HUMANS;
MEDICATION ADHERENCE;
MYOCARDIAL INFARCTION;
PATIENT SELECTION;
PRACTICE GUIDELINES AS TOPIC;
SECONDARY PREVENTION;
|
|
EID: 59549100379
PISSN: 17434297
EISSN: 17434300
Source Type: Journal
DOI: 10.1038/ncpcardio1443 Document Type: Editorial |
|
Times cited : (6)
|
|
References (0)
|